Paul E Schwenn
Overview
Explore the profile of Paul E Schwenn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
42
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Forbes O, Santos-Fernandez E, Wu P, Xie H, Schwenn P, Lagopoulos J, et al.
PLoS One
. 2023 Aug;
18(8):e0288000.
PMID: 37603575
Various methods have been developed to combine inference across multiple sets of results for unsupervised clustering, within the ensemble clustering literature. The approach of reporting results from one 'best' model...
2.
Sacks D, Schwenn P, Boyes A, Mills L, Driver C, Gatt J, et al.
Cereb Cortex
. 2023 Apr;
33(12):8066-8074.
PMID: 37005062
Cross-frequency coupling between the phase of slower oscillatory activity and the amplitude of faster oscillatory activity in the brain (phase-amplitude coupling; PAC), is a promising new biological marker for mental...
3.
Electrophysiological phenotypes of suicidality predict prolonged response to oral ketamine treatment
Can A, Schwenn P, Isbel B, Beaudequin D, Boucas A, Dutton M, et al.
Prog Neuropsychopharmacol Biol Psychiatry
. 2022 Dec;
123:110701.
PMID: 36565983
Oral ketamine has shown to be a rapid-acting antidepressant and a potential treatment option for suicidality, however, repeated doses are often required. Objective markers of prolonged treatment response are needed...
4.
Forbes O, Schwenn P, Wu P, Santos-Fernandez E, Xie H, Lagopoulos J, et al.
Biol Psychol
. 2022 Jul;
173:108403.
PMID: 35908602
Introduction: To better understand the relationships between neurophysiology, cognitive function and psychopathology risk in adolescence there is value in identifying data-driven subgroups based on measurements of brain activity and function,...
5.
Dutton M, Can A, Beaudequin D, Jensen E, Jones M, Gallay C, et al.
J Affect Disord
. 2022 Jan;
300:410-417.
PMID: 35016117
Background: Stress is prevalent in people experiencing suicidality and is a major contributor to the development of mental disorders. Evidence suggests ketamine shows capacity to reverse stress-induced brain changes. Though...
6.
Sacks D, Schwenn P, McLoughlin L, Lagopoulos J, Hermens D
Front Hum Neurosci
. 2021 Apr;
15:622313.
PMID: 33841115
Identifying biomarkers of developing mental disorder is crucial to improving early identification and treatment-a key strategy for reducing the burden of mental disorders. Cross-frequency coupling between two different frequencies of...
7.
Can A, Hermens D, Dutton M, Gallay C, Jensen E, Jones M, et al.
Transl Psychiatry
. 2021 Feb;
11(1):101.
PMID: 33542187
Recently, low-dose ketamine has been proposed as a rapid-acting treatment option for suicidality. The majority of studies to date have utilised intravenous (IV) ketamine, however, this route of administration has...
8.
Lee K, Schwenn P, Smith A, Cavaye H, Shaw P, James M, et al.
Adv Mater
. 2011 Feb;
23(6):766-70.
PMID: 21287639
No abstract available.